Drugs

, Volume 49, Issue 3, pp 362–375 | Cite as

Non-Small-Cell Lung Carcinoma

Current and Future Therapeutic Management
  • Kenneth Bastin
  • Robert Curley
Practical Therapeutics

Summary

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies in developed countries and accounts for millions of deaths worldwide. The incidence of NSCLC correlates with smoking tobacco and is likely to increase in those countries with increasing per capita consumption of tobacco. NSCLC is particularly associated with morbidity — in the US several published clinical studies involving a variety of intensive surgical, chemotherapeutic and radiother-apeutic interventions have produced only a 10% 5-year survival. New technologies and breakthroughs in treatment notwithstanding, the current emphasis in clinical trials is to refine and optimise available therapies to maximise patient disease-free and overall survival. These accruing multi-institutional clinical trials may offer surgical resection with or without neoadjuvant therapy, multiagent chemotherapy, and/or standard or hyperfractionated radiation therapy. Since most NSCLC patients have inoperable disease, the most active current trial design entails chemoradiotherapy, since previous trials appear to suggest superior results to radiotherapy alone in these patients.

Keywords

Lung Cancer Radiation Therapy Oncology Group Bronchogenic Carcinoma Stage IlIA Adis Intemational Limited 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cancer Facts and Figures — 1994. Atlanta, Georgia: American Cancer Society, 1994: 1-29Google Scholar
  2. 2.
    Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Co., 1993: 673–723Google Scholar
  3. 3.
    Hearn W. Emptying the world’s ash trays. Am Med News 1994 Oct 3; 13–15Google Scholar
  4. 4.
    Loeb LA, Ernster VL, Warner KE, et al. Smoking and lung cancer: an overview. Cancer Res 1984; 44: 5940–58PubMedGoogle Scholar
  5. 5.
    Fontham ETH, Correa P, Williams W, et al. Lung cancer in nonsmoking women: a multicenter case-control study. Cancer Epidemiol Biomarkers Prev 1991; 1: 35–43PubMedGoogle Scholar
  6. 6.
    Bastin KT, Mehta MP. Lung cancer mortality in Wisconsin: year 2001. Wis Med J 1992; 91: 343–7PubMedGoogle Scholar
  7. 7.
    Harris CC, Vahakangas K, Autrup H, et al. Biochemical and molecular epidemiology of human cancer risk. Monogr Pathol 1985; 26: 140–67PubMedGoogle Scholar
  8. 8.
    World Health Organization. Histological typing of lung tumors. 2nd ed. Geneva: WHO, 1981Google Scholar
  9. 9.
    Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225–323Google Scholar
  10. 10.
    Beahrs OH, Henson DE, Hutter RVP, et al., editors. Manual for staging of cancer: American Joint Committee on Cancer. 4th ed. Philadelphia: JB Lippincott Co., 1992: 115–22Google Scholar
  11. 11.
    Naruke T, Goya T, Tsuchiya R. Prognosis and survival in resected lung cancer based on the new international staging system. J Thorac Cardiovasc Sur 1988; 96: 440–7Google Scholar
  12. 12.
    Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Ley/Leb antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327: 14–8PubMedCrossRefGoogle Scholar
  13. 13.
    Deslauriers J, Ginsberg RJ, Dubois P, et al. Modern operative morbidity for elective surgical resection in lung carcinoma. Can J Surg 1989; 32: 335–9PubMedGoogle Scholar
  14. 14.
    Ginsberg RJ, Rubinstein L. A randomized comparative trial of lobectomy versus limited resection for patients with T1NO non-small cell lung cancer. Lung Cancer Netherlands 1991; 7 Suppl.: 304Google Scholar
  15. 15.
    Martini N. Surgical treatment of non-small cell lung cancer by stage. Semin Surg Oncol 1990; 6: 248–54PubMedCrossRefGoogle Scholar
  16. 16.
    Komaki R, Mountain CF, Holbert JM. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (MO) at presentation. Int J Radiat Oncol Biol Phys 1990; 19: 31–6PubMedCrossRefGoogle Scholar
  17. 17.
    Burt ME, Pomerantz AH, Bains MS. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin North Am 1987; 67: 987–1000PubMedGoogle Scholar
  18. 18.
    Naruke T, Goya T, Tsuchiya R, et al. The importance of surgery to non-small cell carcinoma of the lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46: 603–10PubMedCrossRefGoogle Scholar
  19. 19.
    Dartevelle PG, Khalife J, Chapelier A. Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases. Ann Thorac Surg 1988; 46: 68–72PubMedCrossRefGoogle Scholar
  20. 20.
    Bastin KT, Mehta MP, Kinsella TJ. Thoracic volume radiation sparing following endobronchial brachytherapy: a quantitative analysis. Int J Radiat Oncol Biol Phys 1993; 25: 703–7PubMedCrossRefGoogle Scholar
  21. 21.
    Bromley LL, Szur I. Combined radiotherapy and resection for carcinoma of the bronchus. Lancet 1955; 5: 937–41CrossRefGoogle Scholar
  22. 22.
    Van Houtte P, Rocmans P, Smets P. Postoperative radiation therapy in lung cancer: a controlled trial after resection of curative design. Int J Radiat Oncol Biol Phys 1980; 6: 983–6PubMedCrossRefGoogle Scholar
  23. 23.
    Bangma PJ. Postoperative radiotherapy. In: Deeley TJ (editor). Carcinoma of the bronchus. New York: Appleton Century Crofts, 1971: 163–70Google Scholar
  24. 24.
    Weisenburger TH. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid carcinoma of the lung. N Engl J Med 1986; 315: 1377–81CrossRefGoogle Scholar
  25. 25.
    Kirsch MM, Sloan H. Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location. Ann Thorac Surg 1982; 33: 459–63CrossRefGoogle Scholar
  26. 26.
    Zhang HX, Yin WB, Zhang LJ. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol 1989; 14: 89–94PubMedCrossRefGoogle Scholar
  27. 27.
    Perez CA, Bauer M, Edelstein S. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 539–47PubMedCrossRefGoogle Scholar
  28. 28.
    Sydel HG, Diener-West M, Urtasun R. Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: preliminary report of a RTOG pilot study. Int J Radiat Oncol Biol Phys 1985; 11: 1841–7CrossRefGoogle Scholar
  29. 29.
    Radiation Therapy Oncology Group Report. Reston (VA): American College of Radiology, 1992a; 9: 1Google Scholar
  30. 30.
    Line DH, Deeley TJ. The necropsy findings in carcinoma findings in carcinoma of the bronchus. Br J Dis Chest 1971; 65: 238–42PubMedCrossRefGoogle Scholar
  31. 31.
    Deslauriers J, Brisson J, Cartier R. Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 1989; 97: 504–12PubMedGoogle Scholar
  32. 32.
    Perez CA, Azarnia N, Cox JD, et al. Sequelae of definitive irradiation in the treatment of carcinoma of the lung. In: Motta G, editor. Lung cancer: advanced concepts and present status. Genoa: Graphica, 1989Google Scholar
  33. 33.
    Russell A, Pajak T, Selim H. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastatses: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 21: 637–43PubMedCrossRefGoogle Scholar
  34. 34.
    Patchell RA, Tibbs PA, Walsh JW. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494–500PubMedCrossRefGoogle Scholar
  35. 35.
    Mehta M, Mackie TR, Levin AB. Radiosurgery for brain metastasis. Contemp Oncol 1991; 5: 12–9Google Scholar
  36. 36.
    Loeffler JS, Alexander E. Radiosurgery for the treatment of intracranial metasis. In: Alexander E, Loeffler JS, Lunsford LD, editors. Stereotactic radiosurgery. New York: McGraw-Hill, 1993: 197–206Google Scholar
  37. 37.
    Reyes L, Parvez Z, Nemoto T. Adrenalectomy for adrenal metastasis from lung carcinoma. J Surg Oncol 1990; 44: 32–4PubMedCrossRefGoogle Scholar
  38. 38.
    Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 1: 1866–72Google Scholar
  39. 39.
    Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 299–306PubMedCrossRefGoogle Scholar
  40. 40.
    Payne DG. Preoperative radiation therapy in non-small cell cancer of the lung. Lung Cancer Netherlands 1991; 7: 47–56CrossRefGoogle Scholar
  41. 41.
    Lung Cancer Study Group. Prepared by Lad T, Wagner H, Piantadosi S. Randomized phase II evaluation of preoperative chemotherapy alone and radiotherapy alone in stage IIIA non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10: 258Google Scholar
  42. 42.
    Skarin A, Jochelson M, Sheldon T. Neoadjuvant chemotherapy in marginally reesectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40: 266–74PubMedCrossRefGoogle Scholar
  43. 43.
    Albain K, Rusch V, Crowley J. Concurrent cisplatin, VP-16 and chest irradiation followed by surgery for stages IIIA and HIB non-small cell lung cancer: a Southwest Oncology Group study [abstract no. 8805]. Proc Am Soc Clin Oncol 1991; 10: 244Google Scholar
  44. 44.
    Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80PubMedCrossRefGoogle Scholar
  45. 45.
    Radiation Therapy Oncology Group. A phase III comparison between concurrent chemotherapy plus radiotherapy, and concurrent chemotherapy plus radiotherapy followed by surgical resection for stage IIIA (N2) non-small cell lung cancer. Reston (VA): American College of Radiology, 1993. Protocol 93-09Google Scholar
  46. 46.
    LeChevalier T, Arrigada R, Tarayvve M. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 417–23PubMedCrossRefGoogle Scholar
  47. 47.
    Dillman RD, Seagren SL, Propert K. A randomized trial of induction chemotherapy plus high dose radiation vs radiation alone in Stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940–5PubMedCrossRefGoogle Scholar
  48. 48.
    Dillman RD, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III non-small cell lung cancer (NSCLC): five-year follow up of CALGB 84-33 [abstract]. Proc Am Soc Clin Oncol 1993; 12: 329Google Scholar
  49. 49.
    Sause W, Scott C, Taylor S, et al. RTOG 8808 ECOG 4588: preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994; 13: 325Google Scholar
  50. 50.
    Radiation Therapy Oncology Group. A three-arm phase III study of concomitant versus sequential chemotherapy and thoracic radiotherapy for patients with locally advanced inoperable non-small cell lung cancer. Reston (VA): American College of Radiology, 1994. Protocol 94-10Google Scholar
  51. 51.
    Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24: 477–82PubMedCrossRefGoogle Scholar
  52. 52.
    Kuboto K, Furuse K, Kawahara M. Phase II trial of cisplatin (C), vindesine (V), mitomycin-C (M) and concurrent split-course radiotherapy for inoperable locally advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 256Google Scholar
  53. 53.
    Schaake-Koning C, Van Den Bogert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524–30PubMedCrossRefGoogle Scholar
  54. 54.
    Trovo MG, Minatel E, Franchin G. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer: a randomized study. Int J Radiat Oncol Biol Phys 1992; 24: 11–5PubMedCrossRefGoogle Scholar
  55. 55.
    Hazuka M, Crowley J, Bunn P. Concurrent daily low dose cisplain combined with chest irradiation in locally advanced non-small cell lung cancer: preliminary results of a Southwest Oncology Group study [abstract]. Proc Am Soc Clin Oncol 1992; 11: 295Google Scholar
  56. 56.
    Stewart LA, Pignon JP, Parmar MKB, et al. A meta-analysis using individual patient data from randomised clinical trials of chemotherapy in non-small cell lung cancer: survival in the supportive care setting [abstract]. Proc Am Soc Clin Oncol 1994; 13: 337Google Scholar
  57. 57.
    Evans WK, Will BP, Wolfson MC, et al. An estimate of the cost-effectiveness of combined modality therapy for stage IIIA/IIIB NSCLC in Canada [abstract]. Proc Am Soc Clin Oncol 1994; 13: 335Google Scholar
  58. 58.
    Radiation Therapy Oncology Group. Phase II accelerated hyperfractionation protocol for bronchogenic carcinoma. Reston (VA): American College of Radiology, 1992. Protocol 92-05Google Scholar
  59. 59.
    Eastern Cooperative Oncology Group. Phase II study of hyperfractionated accelerated radiation therapy for advanced, unresectable non-small cell lung cancer. Denver: Operations OfficeGoogle Scholar
  60. 60.
    Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. J Clin Oncol 1986; 4: 710–5PubMedGoogle Scholar
  61. 61.
    Radiation Therapy Oncology Group. Phase III conventional therapy with or without recombinant β-interferon for patients with locally advanced non-small cell lung cancer. Reston (VA): American College of Radiology, 1993. Protocol 93-04Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Kenneth Bastin
    • 1
  • Robert Curley
    • 1
  1. 1.Departments of Radiation Oncology and Medical OncologyNortheast Regional Cancer Institute and Mercy HospitalScrantonUSA

Personalised recommendations